Neurosarcoidosis: Clinical features, diagnosis, and management

American Journal of Therapeutics

Volumn 20, Issue 3, 2013, Pages 292-299

  Schwendimann, Robert N ^a   Harris, Meghan K ^a   Elliott, Debra G ^a   Menon, Uma ^a   Gonzalez Toledo, Eduardo ^a,b   Zivadinov, Robert ^c   Pressly, Thomas A ^d,e   Kelley, Roger E ^a   Hoque, Romy ^a   Fowler, Marjorie ^a   Maghzi, Amir H ^f   Etemadifar, Masoud ^f   Saadatnia, Mohammad ^f   Minagar, Alireza ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e Shriners Hospitals for Children in Shreveport   (United States)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD4+ CD8+ ratio; Gallium scan; Immunosuppressive therapy; Neurosarcoidosis; Tumor necrosis factor

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; FOLIC ACID; GADOLINIUM PENTETATE; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; BONE; BRAIN REGION; BRAIN VENTRICLE; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIABETES INSIPIDUS; DIAGNOSTIC IMAGING; DRUG EFFICACY; DURA MATER; EARLY DIAGNOSIS; ENTERITIS; EXCITOTOXICITY; HEADACHE; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEPTOMENINX; LIVER DYSFUNCTION; LYMPHOPROLIFERATIVE DISEASE; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOPATHY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPATHY; NEUROSURGERY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; OTOTOXICITY; PARENCHYMA; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PITUITARY STALK; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SERODIAGNOSIS; SPINAL CORD LESION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEUROSURGICAL PROCEDURES; PROGNOSIS; SARCOIDOSIS;

EID: 84880047867     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818637ef     Document Type: Review

References (34)

1. Burns TM. Neurosarcoidosis. ArchNeurol. 2003;60:1166- 1168.
2. Boeck C. Multiple benign sarkoid of the skin. J Cutan Genitourin Dis. 1899;17:543-550.
3. Heerfordt CF. Uber eine Febris uveo-parotidea subchronica an der glandula parotis und der uvea des anges lokalisieret und haufig mit paresen cerebrospinaler nerven kompliaiert. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1909;70:254.
4. Schaumann J. Lymphogranuloma benigna in the light of prolonged clinical observations and autopsy findings. Br J Dermatol. 1936;48:399.
5. Colover J. Sarcoidosis with involvement of the nervous system. Brain. 1948;71:451-475.
6. Kveim MA. En ny og spesifikk kutan-reaksjon ved Boecks sarcoid. En foreløpig meddelelse. Nord Med. 1941;9: 169-172.
7. Lieberman J. Elevation of serum angiotensin-convertingenzyme (ACE) level in sarcoidosis. Am J Med. 1975;59: 365-372.
8. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. QJM. 1999;92:103-117.
9. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24(Suppl 1):80.
10. La Mantia L, Erbetta A. Headache and inflammatory disorders of the central nervous system. Neurol Sci. 2004; 25:S148-S153.
11. Iannuzzi MC, Rybicki, BA, Teiriten, AS. Sarcoidosis. N Engl J Med. 2007;357:2153-2165.
12. Kasturi KS, Murthy VL, Rangasetty UC. Nasal lumps and skin bumps. Am J Med. 2008;121:16-18.
13. Zajicek JP. Neurosarcoidosis. Curr Opin Neurol. 2000;13: 323-325.
14. Mana J. Magnetic resonance imaging and nuclear imaging in sarcoidosis. Curr Opin Pulm Med. 2002;8:457-463.
15. Spencer TS, Campellone JV, Maldonado I, et al. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum. 2004;34:649-661.
16. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004; 182:289-295.
17. Scott TF, Yandora K, Valeri BA, et al. Aggressive therapy for neurosarcoidosis. Arch Neurol. 2007;64:691-696.
18. Baughman RP. Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med. 2002;8:464-469.
19. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002;8:470-476.
20. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157:1864-1868.
21. Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52:875-879.
22. Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49: 1065-1072.
23. Chaussenot A, Bourg V, Chanalet S, et al. Neurosarcoidosis treated with mycophenolate mofetil: Two cases. Rev Neurol (Paris). 2007;163:471-475.
24. Sharma OP. Effectiveness of chlorquine and hydroxychloroquine in treating selected pattents with sarcoidosis with neurological involvement. Arch Neurol. 1998;55: 1248-1254.
25. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159: 508-511.
26. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997; 155:1665-1669.
27. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol. 1997;159: 5157-5161.
28. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human aveolar macrophages. Respir Med. 1997;91:31-39.
29. Peterson JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1661.
30. Sollberger M, Fluri E, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol. 2004;251:760-761.
31. Kobylecki C, Shaunak S. Refractory neurosarcoidosis responsive to infliximab. Pract Neurol. 2007;7:112-115.
32. Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology, and therapeutics. Adv Intern Med. 2000;45:209-257.
33. Bruns F, Pruemer B, Haverkamp U, et al. Neurosarcoidosis: an unusual indication for radiotherapy. Br J Radiol. 2004;77:777-779.
34. Gullapalli D, Phillips LH II. Neurologic manifestations of sarcoidosis. Neurol Clin. 2002;20:59-83.